Lyell Immunopharma, Inc. filed a Form S-3 registration statement with the SEC on November 13, 2026, covering the resale of up to 7,428,040 shares of common stock by selling stockholders who received those shares in a private placement that closed on November 4, 2026.
Key Highlights
- Shares registered: Up to 7,428,040 shares of common stock are covered by this prospectus for resale by selling stockholders.
- Source of shares: All 7,428,040 shares were sold to the selling stockholders in a private placement that closed on November 4, 2026.
- No company proceeds: Lyell Immunopharma will not receive any proceeds from the sale of shares by the selling stockholders under this prospectus.
- Last reported share price: On November 12, 2026, the last reported sale price of the company's common stock was $15.64 per share.
- Registration costs: The company disclosed it is paying the cost of registering the shares and related expenses; selling commissions, transfer taxes, and other selling costs are the responsibility of the selling stockholders.
- Filer classification: The registrant identified itself as a non-accelerated filer and a smaller reporting company.
Lyell Immunopharma's S-3 Shelf Registration: Private Placement Resale Details
Lyell Immunopharma, Inc. (NASDAQ:LYEL), headquartered at 201 Haskins Way, South San Francisco, California, filed a Form S-3 registration statement on November 13, 2026, initiating a shelf registration process under Rule 415 of the Securities Act of 1933. The filing enables selling stockholders to offer and resell up to 7,428,040 shares of the company's common stock from time to time in one or more offerings. According to the filing, all shares being registered originate from a private placement that closed on November 4, 2026.
The prospectus states that Lyell Immunopharma is not offering or selling any shares under this registration statement and will receive no proceeds from any resales by the selling stockholders. The company disclosed it is bearing the cost of registering the shares and associated expenses. The selling stockholders, as described in the filing, may sell shares at fixed prices, at prevailing market prices, at prices related to prevailing market prices, or at negotiated prices, and may use underwriters, broker-dealers, or agents in those transactions.
The filing notes that the registration statement is subject to completion and will not become effective until a further amendment is filed or the SEC determines an effective date under Section 8(a) of the Securities Act. The prospectus also contains forward-looking statements, which the company characterizes as subject to known and unknown risks and uncertainties, cautioning that actual results may differ significantly from those expressed in any such statements.
What Was Disclosed
Lyell Immunopharma filed a Form S-3 registration statement on November 13, 2026, to register 7,428,040 shares of common stock for resale by selling stockholders, all of whom received their shares in a private placement closed November 4, 2026. The company will not receive proceeds from these resales.




Please wait processing your request...